Results 11 to 20 of about 416,036 (340)

A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

BMC Cancer, 2022
Background Concurrent chemoradiotherapy (CCRT) has become the cornerstone of treatment for patients with locally advanced non-small cell lung cancer (LA-NSCLC). The aim of this study was to compare the efficacies and toxicities of different CCRT regimens
Qiangqiang Zheng, Shihui Min, Yunfeng Zhou   +2 more
doaj   +1 more source

The Mechanotransduction Channel and Organic Cation Transporter Are Critical for Cisplatin Ototoxicity in Murine Hair Cells

Frontiers in Molecular Neuroscience, 2022
Cisplatin is one of the most widely used chemotherapeutic drugs across the world. However, the serious ototoxic effects, leading to permanent hair cell death and hearing loss, significantly limit the utility of cisplatin.
Jinan Li, Chang Liu, Samuel Kaefer, Mariam Youssef, Bo Zhao   +4 more
doaj   +1 more source

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, Mary W., Stordal, Britta
core   +2 more sources

Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]

, 2009
Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
B Stordal, B Stordal, BK Stordal, H Kawai, H Kuroda, M Markman, S Henness, V Dieras   +7 more
core   +2 more sources

Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration [PDF]

, 2014
Cisplatin is a highly emetogenic cancer chemotherapy agent, which is often used to induce nausea and emesis in animal models. The cytotoxic properties of cisplatin also cause adverse events that negatively impact on animal welfare preventing repeated ...
A Tidholm, BD Rose, CC Horn, CL Limebeer, DC Dale, DM Vail, E Portillo, EM Rock, G Jang, GK Ogilvie, GK Ogilvie, GP Chrousos, GR Morrow, H Imamura, Hannah Kenward, IK Vonderen van, J Ito, J Loor, JD Chen, Jonathan Elliott, K Barabas, K Olsson, KL Koch, L Kelland, LA Parker, LA Parker, Ludovic Pelligand, LX Cubeddu, LX Cubeddu, M Boer-Dennert de, M Fredrikson, M Minami, MK Samson, MS Kim, N Percie du Sert, N Percie du Sert, PL Andrews, PL Andrews, PL Andrews, RD Fisher, S Ina, S Robery, SD Caras, T Bloom, V Napadow, VA Puente-Redondo de la, X Yu   +46 more
core   +2 more sources

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation

Journal of Pharmacological Sciences, 2015
Cisplatin is a chemotherapeutic drug but induces acute kidney injury (AKI). Cisplatin-induced AKI depends on several signaling pathways leading to apoptosis in tubular epithelial cells.
Hyun-Jung Kim, Dong Jun Park, Jin Hyun Kim, Eun Young Jeong, Myeong Hee Jung, Tae-Ho Kim, Jung Ill Yang, Gyeong-Won Lee, Hye Jin Chung, Se-Ho Chang   +9 more
doaj   +1 more source

Cisplatin decreases HOXA13 and alphaVBeta3 integrin levels in the uterus

Taiwanese Journal of Obstetrics & Gynecology, 2021
Objective: To examine the effects of cisplatin on uterine histology and implantation molecules and the possible protective role of recombinant Klotho administration on uterine histology and uterine receptivity in mice exposed to cisplatin.
Mustafa Albayrak, Ismail Biyik, Fikriye Yasemin Ozatik, Orhan Ozatik, Neziha Senem Ari, Yasemin Teksen, Ozlem Erten   +6 more
doaj   +1 more source

Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity [PDF]

, 2017
Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea.
Bhatta, Puspanjali, Borse, Vikrant, Dhukhwa, Asmita, FH Al Aameri, Raheem, Ghosh, Sumana, Kaur, Tejbeer, Lowy, Michelle, Mukherjea, Debashree, Ramkumar, Vickram, Rybak, Leonard P, Sheehan, Kelly, Sheth, Sandeep, Tupal, Srinivasan   +12 more
core   +2 more sources

The endocannabinoid/cannabinoid receptor 2 system protects against cisplatin-induced hearing loss [PDF]

, 2018
Previous studies have demonstrated the presence of cannabinoid 2 receptor (CB2R) in the rat cochlea which was induced by cisplatin. In an organ of Corti-derived cell culture model, it was also shown that an agonist of the CB2R protected these cells ...
Asmita Dhukhwa, Debashree Mukherjea, Kelly Sheehan, Leonard P. Rybak, Leonard P. Rybak, Sandeep Sheth, Sumana Ghosh, Vickram Ramkumar, Vikrant Borse   +8 more
core   +4 more sources